Lightnews — Scholar-powered news

OncLive @onclive.bsky.social · 15m

OST-HER2 Displays Potential OS Benefit in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma #sarcoma #oncology www.onclive.com/view/ost-her...

OST-HER2 Displays Potential OS Benefit in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | OncLive

OST-HER2 produced a potential overall survival benefit at 2 years in recurrent, fully resected, pulmonary metastatic osteosarcoma.

www.onclive.com

OncLive @onclive.bsky.social · 19h

Fruquintinib Represents Viable Later-Line Option for mCRC As Access Expands for Patients @mdanderson.bsky.social #oncology #crc #colorectalcancer
www.onclive.com/view/fruquin...

Fruquintinib Represents Viable Later-Line Option for mCRC As Access Expands for Patients | OncLive

Kanwal P.S. Raghav, MBBS, MD, discusses the role of fruquintinib for the treatment of patients with later-line colorectal cancer.

www.onclive.com

OncLive @onclive.bsky.social · 20h

#MPN Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 #oncology #hematology

Read the full article ⬇️
www.onclive.com/view/mpn-mon...

MPN Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 | OncLive

Check out this September recap of OncLive’s coverage of the top news and expert insights in myeloproliferative neoplasms.

www.onclive.com

OncLive @onclive.bsky.social · 21h

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed #Myeloma #oncology

www.onclive.com/view/daratum...

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed Myeloma | OncLive

Daratumumab plus lenalidomide, with reduced exposure to dexamethasone, led to a PFS improvement in frail, newly diagnosed multiple myeloma.

www.onclive.com

OncLive @onclive.bsky.social · 1d

ONO-4578 Plus Nivolumab/Chemo Improves PFS in HER2– Advanced Gastric Cancer #stomachcancer #oncology www.onclive.com/view/ono-457...

ONO-4578 Plus Nivolumab/Chemo Improves PFS in HER2– Advanced Gastric Cancer | OncLive

ONO-4578 plus nivolumab and chemotherapy improved PFS in HER2-negative advanced gastric cancer.

www.onclive.com

OncLive @onclive.bsky.social · 1d

The FDA Grants Fast Track Designation to ADCE-D01 for Soft Tissue #Sarcoma. #oncology

www.onclive.com/view/fda-gra...

FDA Grants Fast Track Designation to ADCE-D01 for Soft Tissue Sarcoma | OncLive

The FDA granted fast track designation to ADCE-D01 for the treatment of soft tissue sarcoma.

www.onclive.com

OncLive @onclive.bsky.social · 1d

GI oncology experts share insights on the most anticipated abstracts upcoming at the #ESMO25 Congress. @mdanderson.bsky.social @mayocliniccancer.bsky.social @clevelandclinic.bsky.social @myesmo.bsky.social #oncology

Sign up to read their full insights! ⬇️
www.onclive.com/view/esmo-20...

OncLive @onclive.bsky.social · 1d

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma @bloodadvances.bsky.social #lymsm #hematology #oncology
www.onclive.com/view/poor-re...

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma | OncLive

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

www.onclive.com

OncLive @onclive.bsky.social · 1d

Eribulin Plus Pyrotinib Displays Efficacy in Trastuzumab-Resistant HER2+ #BreastCancer. #BCAM #BreastCancerAwarenessMonth #oncology

www.onclive.com/view/eribuli...

Eribulin Plus Pyrotinib Displays Efficacy in Trastuzumab-Resistant HER2+ Breast Cancer | OncLive

Eribulin with pyrotinib was safe and active in patients with HER2-positive advanced breast cancer who were resistant to treatment with trastuzumab.

www.onclive.com

1

OncLive @onclive.bsky.social · 1d

Urothelial Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025 #oncology #urothelialcancer #urology
www.onclive.com/view/urothel...

OncLive @onclive.bsky.social · 1d

BREAKING 🚨: @fda.gov Approves Adjuvant Cemiplimab for Cutaneous Squamous Cell Carcinoma #cscc #oncology

Read more: onclive.com/view/fda-app...

OncLive @onclive.bsky.social · 1d

FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma
#oncology #lcsm #mesothelioma
www.onclive.com/view/fda-gra...

FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma | OncLive

VT3989 has received fast track designation from the FDA for unresectable malignant nonpleural or pleural mesothelioma after progression on prior therapy.

www.onclive.com

OncLive @onclive.bsky.social · 1d

WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy @fda.gov #melsm #oncology
www.onclive.com/view/wtx-124...

WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy | OncLive

WTX-124 has received fast track designation from the FDA for locally advanced or metastatic cutaneous melanoma after standard-of-care immunotherapy.

www.onclive.com

OncLive @onclive.bsky.social · 2d

FDA Issues CRL for Dasatinib in Chronic Myeloid #Leukemia #oncology

www.onclive.com/view/fda-app...

FDA Issues CRL for Dasatinib in Chronic Myeloid Leukemia | OncLive

The FDA has approved dasatinib, a next-generation formulation of a protein kinase inhibitor, for the treatment of patients with chronic myeloid leukemia.

www.onclive.com

OncLive @onclive.bsky.social · 2d

Targeted Therapies Move the Needle in #NSCLC #oncology

www.onclive.com/view/taarget...

Targeted Therapies Move the Needle in NSCLC | OncLive

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

www.onclive.com

OncLive @onclive.bsky.social · 2d

CDK4/6 Inhibition With Palbociclib Displays Activity in Low-Grade Serous Ovarian Cancer
#OvarianCancer #gyncsm
www.onclive.com/view/cdk4-6-...

CDK4/6 Inhibition With Palbociclib Displays Activity in Low-Grade Serous Ovarian Cancer | OncLive

CDK4/6 inhibition with palbociclib demonstrated encouraging efficacy in patients with low-grade serous ovarian cancer.

www.onclive.com

1

OncLive @onclive.bsky.social · 2d

NICE Recommends First-Line Lorlatinib for Newly Diagnosed ALK+ #NSCLC #oncology

www.onclive.com/view/nice-re...

NICE Recommends First-Line Lorlatinib for Newly Diagnosed ALK+ NSCLC | OncLive

Lorlatinib has received NICE’s recommendation for untreated advanced non–small cell lung cancer.

www.onclive.com

OncLive @onclive.bsky.social · 2d

Dana-Farber Proposes Proton Therapy Center, Offering Leading Edge Treatment to Patients
@danafarber.bsky.social #Oncology

www.onclive.com

OncLive @onclive.bsky.social · 3d

sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer #BreastCancer #bcsm #oncology
www.onclive.com/view/snda-su...

sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer | OncLive

A new drug application was submitted to Japan’s Ministry of Health, Labour and Welfare for T-DXd plus pertuzumab for HER2-positive breast cancer.

www.onclive.com

OncLive @onclive.bsky.social · 3d

HyBryte Has an Acceptable Safety Profile in Cutaneous T-Cell #Lymphoma #oncology

www.onclive.com/view/hybryte...

HyBryte Has an Acceptable Safety Profile in Cutaneous T-Cell Lymphoma | OncLive

A Data Monitoring Committee confirmed that the safety profile of HyBryte is acceptable and that the agent is not associated with safety concerns in CTCL.

www.onclive.com

OncLive @onclive.bsky.social · 3d

AI Integration and Systemic Reform Are Needed to Balance Resource Protection With Timely Access to Treatment
#oncology #AI
www.onclive.com/view/ai-inte...

AI Integration and Systemic Reform Are Needed to Balance Resource Protection With Timely Access to Treatment | OncLive

Emerging technologies and process reconsiderations may alleviate time and resource stressors oncology teams face when appealing patient insurance denials.

www.onclive.com

OncLive @onclive.bsky.social · 3d

The FDA Approval of Intravesical Mitomycin in #NMIBC Follows #ODAC Debate on Need for Randomized Data

Read more here ⬇️
www.onclive.com/view/fda-app...

FDA Approval of Intravesical Mitomycin in NMIBC Follows ODAC Debate on Need for Randomized Data | OncLive

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

www.onclive.com

OncLive @onclive.bsky.social · 3d

Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL #leusm #hematology
www.onclive.com/view/retrosp...

Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL | OncLive

BTK inhibitor therapy improved PFS vs chemoimmunotherapy in NOTCH1-mutated CLL, highlighting the value of NOTCH1 screening to guide treatment selection.

www.onclive.com

OncLive @onclive.bsky.social · 3d

New Study Links Genetic Variation to Chemotherapy-Related Liver Damage in Patients With Colorectal Cancer Liver Metastases @mayocliniccancer.bsky.social @mayoclinic.org #crcsm #oncology
www.onclive.com/view/new-stu...

New Study Links Genetic Variation to Chemotherapy-Related Liver Damage in Patients With Colorectal Cancer Liver Metastases | OncLive

A genetic factor may explain why some patients with colorectal cancer that has spread to the liver experience liver damage after chemotherapy.

www.onclive.com

OncLive @onclive.bsky.social · 4d

First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC #oncology #bcsm #TNBC
www.onclive.com/view/first-l...

First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC | OncLive

Dato-DXd displayed topline survival benefits in patients with recurrent/metastatic TNBC who could not receive immunotherapy.

www.onclive.com